These localized changes in the bone marrow microenvironment (BMME) explain why traditional therapies for MDS/AML, including chemotherapeutics and hypomethylating agents, are not as effective in <i>TP53</i>-mutated myeloid neoplasms and demonstrate the dire need for new treatments in this patient population. Here, TP53 is linked to myeloid neoplasm.